Guggenheim Securities, LLC has released a statement on behalf of former Pfizer executives Ian Read and Frank D'Amelio, indicating that they have chosen not to engage with Starboard Value in its campaign concerning Pfizer. They have expressed their full endorsement of Pfizer's Chairman and CEO, Albert Bourla, as well as the senior management team and board, expressing confidence in their ability to generate shareholder value in the long term.
Recent reports from the Wall Street Journal have highlighted that activist investor Starboard Value has acquired an approximately $1 billion stake in Pfizer, urging significant changes to improve the company's underwhelming performance.
While the details of Starboard's proposed strategies remain undisclosed, the firm has reportedly approached Ian Read and Frank D'Amelio, who were previously open to supporting Starboard's efforts for revitalizing the company's performance, according to the Journal.
